On July 23, 2020, CGD Senior Fellow Prashant Yadav appeared before the House Ways and Means Subcommittee on Trade at a hearing titled “Trade, Manufacturing, and Critical Supply Chains: Lessons From COVID-19.” Yadav’s testimony noted the vulnerabilities in supply chains for medical products clearly exposed by the COVID-19 pandemic and outlined key considerations for US policy toward medical supply chains moving forward.
Substantial evidence has emerged relating to the potential magnitude of the indirect health effects of the coronavirus pandemic.This paper provides an overview of the lessons learned from previous outbreaks and economic crises in relation to indirect health effects as well as a framework for adopting a whole of health approach to the COVID response.
On June 16, 2020, Amanda Glassman submitted evidence to the United Kingdom's House of Commons International Development Committee on humanitarian crises monitoring and the impact of coronavirus.
Community health workers (CHWs) are often the first point of care for vulnerable and underserved populations in low- and middle-income countries, but do they have the PPE they need to do their jobs?
Diagnostic testing is at the center of the policy debate around COVID-19 interventions in India. As of June 1, 2020, India had conducted approximately 3.8 million tests since it began testing in February, but many experts have noted that testing capacity is still drastically insufficient for the needs of the population.
This paper assesses Colombia’s recent expansion in comprehensive early childhood care, underscoring the importance of strong high-level political commitment, inter-institutional coordination and stable financing.
Leave No One Behind: Using a Benefit-Based Advance Market Commitment to Incentivise Development and Global Supply of COVID-19 Vaccines
The global effort to control the COVID-19 pandemic has seen an exceptional allocation of public and philanthropic funds to advance the development of diagnostics, therapeutics, and vaccines as quickly as possible. While critical, even these significant commitments represent only a “down payment” on a price tag that could eventually exceed $50 billion just to scale the production of vaccines to control this global pandemic—amounts that cannot be raised through traditional donor and philanthropic commitments.
Times of economic uncertainty, civil unrest and disaster are linked to a myriad of risk factors for increased violence against women and children (VAW/C). Pandemics are no exception.
Financing and Scaling Innovation for the COVID Fight: A Closer Look at Demand-Side Incentives for a Vaccine
As the COVID-19 pandemic accelerates, global leaders are quickly realizing that we need a bigger, better toolbox to effectively fight the novel coronavirus.
As the UK undertakes “the biggest review of Britain's place in the world since the end of the Cold War,” our experts explore how global health could be incorporated into the integrated review.
The novel coronavirus outbreak that emerged in late 2019 has infected tens of thousands in China, community transmission is feared in other countries, and containment looks increasingly unlikely.
Unpacking the Black Box of Payer Policy: A Demand-Side Approach for Equitable Uptake of Cost-Effective Health Innovation
Over the past two decades, global health innovation has delivered important new tools for use in low- and middle-income countries (LMICs) and saved many lives. Nonetheless, the current innovation ecosystem suffers from significant limitations that are likely to worsen with aid transition.
The market-driven, value-based advance commitment (MVAC) builds on the advance market commitment (AMC) mechanism previously used in global health with several important innovations and improvements. Most crucially, the MVAC is driven by MIC demand rather than donor contributions; is informed by countries’ ability to pay rather than a single, “cost-plus” price; and allows pharmaceutical companies to reap higher revenues from a more effective product. In this report, we apply our new model—the MVAC—to a target product profile (TPP), published by the World Health Organization (WHO) in 2016 and endorsed by BMGF, for a pan-TB regimen.
Sugar, Rum, and Tobacco: Domestic Resource Mobilization for Low-Income Countries through Excise Taxes
The paper provides a comprehensive overview of issues relevant to using health taxes to raise revenues in low-income countries. The paper argues that in low-income countries, health taxes can raise enough revenue to make them worthwhile and that health taxes may be better candidates for mobilizing domestic resources than some other taxes.
New technology, better use of data, and entrepreneurial passion in improving distribution channels is reaching a critical mass with the potential to drive extraordinary improvements in availability, affordability, and quality of health products. Global health institutions can play a significant role in further boosting the overall innovation ecosystem for health products distribution. However, most distribution system innovators are missing from global discussions around UHC and access to medicines.
Mind the Gaps: Takeaways from Emerging Research and Policy Implications for Aid Transition in Health and Development
As countries grow economically, governments face rapidly growing demands for quality, affordable, accessible, and equitable healthcare and other social services. At the same time, many middle-income countries face the prospect of transitioning away from donor aid, adding pressure to already-constrained public budgets to fill gaps as donor support ramps down.
This note outlines the organizations and research initiatives currently addressing taxation of tobacco, alcohol, and sugar-sweetened beverages—the “bads”—to help navigate the landscape of existing research and identify gaps and opportunities for further work.
The arrival of a new leadership team in Brussels provides an opportunity for Europe to reinvigorate its role as a global development power and to build a true partnership with its continental neighbour, Africa. These tasks have never been more urgent. Read here for recommendations on global health policy.